A Clinical Study of EUS-RFA for Inoperable Pancreatic Ductal Adenocarcinoma

C

Centre hospitalier de l'Université de Montréal (CHUM)

Status

Suspended

Conditions

Pancreatic Ductal Adenocarcinoma

Treatments

Device: EUS-RFA using Habib Tm as a probe
Procedure: EUS

Study type

Interventional

Funder types

Other

Identifiers

NCT03444948
CE 17.215

Details and patient eligibility

About

To assess if endoscopic ultrasound-guided radiofrequency ablation application in patients with inoperable pancreatic cancer confers survival benefit when compared to patients receiving standard medical care.

Full description

The five-year survival for pancreatic ductal adenocarcinoma (PDAC) is less than 5% in spite of the advances in management of cancers in the last few decades. Endobiliary application of radiofrequency (RF) has been developed and used in patients with inoperable bile duct and pancreatic head adenocarcinomas presenting with biliary obstruction. (1, 2) Endoscopic ultrasound (EUS) radiofrequency ablation (RFA) of pancreatic neoplasms has been proven to be well tolerated and safe, inducing a significant reduction in tumour size (3). Various techniques of EUS-guided tumour ablation have been described, including RF ablation, photodynamic therapy, laser ablation, and ethanol injection (4). Kahaleh et al. have demonstrated that Endoscopic ultrasound guided RF ablation (EUS-RFA) of the pancreatic head using Habib EUS-RFA catheter (EMcision Ltd, UK) through a 19-gauge needle was well tolerated in 5 Yucatan pigs and with minimum amount of pancreatitis (5). In a pilot clinical study, Pai et al showed either a complete response or at least a 50% reduction in tumours following application of radiofrequency ablation with the Habib™ EUS-RFA device in a group of eight patients with pancreatic cancers (3).

Enrollment

108 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients above 18 years of age.
  • A cytological / histological diagnosis of inoperable PDAC based on multidisciplinary review of cross-sectional imaging and cytology / histology results.
  • Patients ought to be fit enough to be considered for the study (ECOG (Eastern Cooperative Oncology Group) performance status 0, 1 or 2)
  • Patients who have commenced chemotherapy are not excluded from the study
  • Patients capable of giving informed consent
  • Negative blood pregnancy test for women of childbearing potential
  • Willingness and ability to comply with all protocol requirements including scheduled visits, treatment plans, laboratory tests and other study procedures.

Exclusion criteria

  • ECOG performance status 3 or 4
  • Life expectancy less than 3 months (including liver metastases, carcinomatosis)
  • Prior investigational drugs within the last 30 days
  • Known infection with human immunodeficiency virus (HIV)

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

108 participants in 2 patient groups

3 radiofrequency ablation procedures
Experimental group
Description:
Subject will undergo 3 radiofrequency ablation procedures at 1 month intervals (EUS-RFA using Habib Tm as a probe)
Treatment:
Device: EUS-RFA using Habib Tm as a probe
standard medical care
Active Comparator group
Description:
Subject will receive standard medical care, including pain relief drugs
Treatment:
Procedure: EUS

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems